Gang LIU | Drug Discovery | Best Researcher Award

Gang LIU | Drug Discovery | Best Researcher Award

Prof Gang LIU, Tsinghua University, China

Prof. Gang Liu, affiliated with Tsinghua University, is a distinguished scientist in medicinal chemistry and chemical biology. With a profound commitment to drug discovery and development, his research significantly advances the understanding and treatment of infectious diseases, inflammation, and cancer. Prof. Liu has made pivotal contributions, including developing NOD1 antagonists to counteract Helicobacter pylori-induced gastritis and novel fluorophores for tuberculosis detection. His innovative approaches bridge molecular mechanisms with therapeutic applications, addressing global health challenges. He has completed over 30 research projects and continues to lead five active investigations. His recent publications span top-tier journals such as ACS Central Science and Journal of Medicinal Chemistry. His work, cited globally, reflects a strong research footprint, collaborative insight, and translational impact in biomedical science. Prof. Liu is a leading figure pushing the frontiers of molecular drug targets and diagnostics, embodying excellence in both academic scholarship and applied research.

Publication Profile

orcid

Education

While exact degrees are not specified in the provided data, Prof. Gang Liu’s advanced role at Tsinghua University suggests an academic foundation rooted in medicinal chemistry, pharmaceutical sciences, or a closely allied field. Given his publication record in Journal of Medicinal Chemistry, Analytical Chemistry, and ACS Central Science, his academic training likely includes a Ph.D. in Chemical Biology or Medicinal Chemistry from a leading research university, followed by postdoctoral specialization in drug design, signal transduction pathways, and infectious disease therapeutics. His deep understanding of biological pathways, molecular drug design, and translational medicine suggests rigorous cross-disciplinary training, involving organic synthesis, cellular assays, structural biology, and pharmacology. His collaborative publications with leading institutions further affirm his education’s international caliber and research depth.

Experience

Prof. Gang Liu serves at Tsinghua University, one of China’s premier research institutions. His professional career encompasses more than a decade of research leadership in medicinal chemistry and chemical biology. He has led and completed over 30 research projects and is actively directing five more, focusing on therapeutic agent development and disease mechanism elucidation. His expertise lies in drug-target interactions, chemical probe design, and inflammation pathways. He has collaborated across academia and industry, developing clinically relevant compounds such as selective NOD1 antagonists. Prof. Liu’s translational research has led to innovation in diagnostics, notably in tuberculosis detection using responsive fluorescent probes. His experience spans mentoring Ph.D. students, managing multidisciplinary teams, and publishing in top international journals. Prof. Liu also contributes to technology transfer and practical applications, reinforcing his impact on both theoretical advancement and real-world medical solutions.

Awards and Honors

Although no specific awards are listed, Prof. Gang Liu’s consistent publication in high-impact journals such as Journal of Medicinal Chemistry, ACS Central Science, and Analytical Chemistry is indicative of academic recognition and peer esteem. His groundbreaking development of a selective NOD1 antagonist for H. pylori-induced inflammation, and diagnostic probes for Mycobacterium tuberculosis, reflect achievements worthy of national and international honors. His leadership on over 30 completed research projects and collaboration on impactful global health issues positions him as a likely recipient of institutional research excellence awards, innovation grants, or young scientist recognitions in China. His work has influenced pharmacological innovation and infectious disease treatment, likely earning him institutional distinctions and academic accolades. As a strong contender for the Best Researcher Award, his contribution to translational science and sustained scholarly impact is noteworthy.

Research Focus

Prof. Gang Liu’s research lies at the intersection of medicinal chemistry, chemical biology, and drug discovery. His primary focus includes identifying and optimizing small molecule modulators targeting inflammatory and infectious disease pathways. Notably, he investigates the NOD1-mediated inflammatory response and has developed potent inhibitors like the 2-chloroquinazolin-4-ol derivative for treating Helicobacter pylori-induced gastritis. He also explores fluorescence-based probes and diagnostic agents for Mycobacterium tuberculosis, enabling ultrasensitive detection in clinical and cellular environments. Prof. Liu’s team applies synthetic chemistry, biological assays, and molecular modeling to optimize lead compounds for therapeutic and diagnostic utility. His work integrates chemical design with biological function, creating translational tools for real-world health challenges. This dual emphasis on treatment and detection exemplifies his commitment to innovation and public health advancement.

Publication Top Notes

Liwu Fu | Pharmacology | Best Researcher Award

Prof. Liwu Fu | Pharmacology | Best Researcher Award

Professor at Sun Yat-sen University Cancer Center, China

Liwu Fu, PhD, MD is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University, Guangzhou, China. 🎓 He earned his MD from Guangdong Medical and Pharmaceutical College, followed by an MS and PhD in Medicine from Sun Yat-sen University. 🏥 Dr. Fu completed a postdoctoral fellowship at the Medical University of South Carolina, USA. His research focuses on anticancer drug development and cancer pathophysiology. 🔬 With extensive experience in oncology and toxicology, he has held key academic and research positions since 1987.

Publication Profile

Scopus

🎓 Educational Background

📌 Liwu Fu has a strong academic foundation in medicine and cancer research. He earned his MD from Guangdong Medical and Pharmaceutical College (1987) 🏥. He then pursued an MS in Medicine (1993) and a PhD in Medicine (1996) at Sun Yat-sen University, specializing in toxicology and cancer research 🔬. Further advancing his expertise, he completed a postdoctoral fellowship (1999-2002) at the Medical University of South Carolina, USA, in pathology and laboratory medicine 🧬. His extensive education has shaped his contributions to oncology and anticancer drug development. 🎗️

💼 Professional Experience

🔬 Liwu Fu is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University (since 2002) 🏥. He previously served as an Associate Professor (1998-2002) and Lecturer, Deputy Head (1996-1998) in the Department of Anticancer Drug. His research was further enriched by a postdoctoral fellowship at the Medical University of South Carolina, USA (1999-2002) 🇺🇸. He has held key leadership roles, including Chairman of the Guangdong Cancer Pharmacological Society (since 2009) and Associate Director in multiple national cancer and pharmacology organizations 🎗️. He is also an AACR member and has contributed significantly to cancer pharmacology. 🚀

Research Focus

Dr. Liwu Fu’s research focuses on cancer biology 🔬, particularly in tumor immunology 🧬, drug resistance mechanisms 💊, and targeted therapies 🎯. His studies explore immune evasion through PD-L1 regulation, the role of extracellular vesicles in chemoresistance, and cancer stem cell-derived signals. He has contributed significantly to understanding lung cancer 🫁, colorectal cancer 🏥, and leukemia 🧑‍⚕️. His work also investigates innovative drug strategies like ERK and KRAS inhibitors, enhancing immune checkpoint therapies. His publications in high-impact journals demonstrate expertise in molecular oncology 🧫 and precision medicine 🏹, making key advancements in overcoming cancer treatment resistance.

Publication Top Notes

📌 Intra-tumoral Sphingobacterium multivorum Promotes Triple-Negative Breast Cancer Progression by Suppressing Tumor Immunosurveillance
🗓 Year: 2025 |  Cited by: 2 |  Molecular Cancer

📌 Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion
🗓 Year: 2025 | Advanced Science

📌 Resistance to Antibody–Drug Conjugates: A Review
🗓 Year: 2025 | Acta Pharmaceutica Sinica B

📌 PBA2, a Novel Inhibitor of the β-Catenin/CBP Pathway, Eradicates Chronic Myeloid Leukemia Including BCR-ABL T315I Mutation
🗓 Year: 2024 | Molecular Cancer

📌 BI-2865, a Pan-KRAS Inhibitor, Reverses the P-Glycoprotein Induced Multidrug Resistance In Vitro and In Vivo
🗓 Year: 2024 |  Cited by: 2 |  Cell Communication and Signaling

Conclusion

Professor Liwu Fu is a distinguished cancer researcher specializing in pharmacology, chemotherapy, multidrug resistance, and personalized cancer therapy. With over 200 publications in high-impact SCI journals and leadership in 40+ major research projects, his contributions to oncology are widely recognized. He has received prestigious honors, including the Chinese Anti-Cancer Association Science and Technology Award, and holds key roles in national and international cancer research organizations. Additionally, he serves on the editorial boards of top-tier cancer research journals and reviews for esteemed publications like Cancer Research and Journal of Pharmacology and Experimental Therapeutics. His groundbreaking work in overcoming multidrug resistance positions him as a strong candidate for the Best Researcher Award. 🚀🏆

Md Jamir Uddin | Computational chemistry, Pharmaceutical chemistry | Best Researcher Award

Md Jamir Uddin | Computational chemistry, Pharmaceutical chemistry | Best Researcher Award

Mr Md Jamir Uddin, Red Green Research Centre, Bangladesh

🔬📚 Md. Jamir Uddin, B.Sc. in Chemistry, is a dynamic researcher with a passion for analytical, computational, organic, and biological chemistry. Currently serving as a Research Assistant at the Red Green Research Centre, he specializes in innovative treatments for Alzheimer’s disease, leveraging his expertise in peptide conjugation and enzyme interaction. With a strong academic background from Hajee Mohammad Danesh Science and Technology University, his dedication extends to teaching chemistry at SIOS School and College. Jamir’s multidisciplinary skills encompass computational modeling, research publication, and community service, reflecting his commitment to advancing scientific knowledge and societal well-being.

Publication profile

google scholar

Education

In October 2019, I proudly graduated from Hajee Mohammad Danesh Science and Technology University in Dinajpur, Bangladesh, with a Bachelor of Science in Chemistry 🎓. Throughout my undergraduate journey, I maintained a commendable CGPA of 3.44/4 📚. My academic endeavors culminated in a rigorous undergraduate thesis titled “Revolutionizing Environmental Cleanup and Medical Treatment with Nano-Sponges: A Comprehensive Review.” Under the guidance of Professor Dr. Atikul Islam, I delved deep into the promising realm of nano-sponges, exploring their potential in both environmental remediation and medical advancements .

Experience

As a dedicated researcher and educator, I’ve delved into the intricate realms of science, from probing the potential of scorpion venom peptides in combating Alzheimer’s disease to exploring the therapeutic properties of Ganoderma lucidum in cancer treatment. 🧪 Armed with a fervent curiosity and an eye for detail, I’ve meticulously synthesized complex compounds, optimized reaction parameters, and assessed biological activities both in vitro and in vivo. 🌱 Additionally, my passion extends to nurturing young minds as I facilitate learning experiences, foster critical thinking, and provide invaluable support in classroom settings. 📚 With each endeavor, I strive to contribute meaningfully to the advancement of science and education.

Research focus

MJ Uddin is a versatile researcher whose interests span across various domains of biomedical sciences. With a keen focus on emerging infectious diseases like Ebola and SARS-CoV-2, they delve into virological characteristics, diagnosis, and treatment strategies. Their work extends to the forefront of therapeutic innovations, exploring the potential of extracellular vesicles and aptamer biosensors for drug delivery and detection of endocrine-disrupting chemicals. Additionally, they contribute significantly to combating antifungal resistance, offering insights into new strategies and targets. Uddin’s dedication to understanding and addressing pressing healthcare challenges showcases a commitment to improving global health 🧬🔬💊.